New molecular bioassays for the estimation of the teratogenic potency of valproic acid derivatives in vitro: activation of the peroxisomal proliferator-activated receptor (PPARdelta).
Therapy with the antiepileptic drug valproic acid (2-propylpentanoic acid, VPA) during early pregnancy can cause teratogenic effects (neural tube defects) in humans and in mice. VPA and a teratogenic derivative specifically induce differentiation of F9 teratocarcinoma cells and activate PPARdelta. We have now studied structure-activity relationships of 11 VPA-related compounds by quantitatively comparing their teratogenic potency with their effects in the two novel in vitro systems. Based on the induction of a Rous sarcoma virus (RSV) promoter-driven reporter gene, which is associated with the differentiation of F9 cells, a system suitable for high-throughput and quantitative screening was established. Structure-activity investigations showed that only teratogenic derivatives of VPA induced the response in F9 cells as well as activated the PPARdelta-dependent reporter system in Chinese hamster ovary (CHO) cells. Increases in the length of the side chain in the VPA-related 2-alkyl-pentynoic acid generate more potent inducers in the cell-culture-based assays, which also show higher teratogenicity and embryonic lethality rates. Activation of PPARdelta correlated well with the effects in the F9 cell assay and with teratogenic potency in vivo (p < 0.007). Evaluation of the effects of the presented set of compounds allows the conclusion that the in vitro systems faithfully reflect teratogenicity of VPA-related compounds. Whether the activation of PPARdelta is causally related to the disruption of proper embryonic development or whether it reflects other yet unknown VPA-induced events remains to be established.
Lampen
A
A
Zentrumsabteilung für Lebensmitteltoxikologie, Tierärztliche Hochschule Hannover, Hannover, Germany.
Siehler
S
S
Ellerbeck
U
U
Göttlicher
M
M
Nau
H
H
D000818:Animals; D000927:Anticonvulsants / Q000737:chemistry / Q000633:toxicity*; D001358:Avian Sarcoma Viruses / Q000235:genetics; D001681:Biological Assay / Q000379:methods*; D016466:CHO Cells / Q000187:drug effects* / Q000378:metabolism / Q000821:virology; D002454:Cell Differentiation / Q000187:drug effects; D006224:Cricetinae; D017931:DNA Primers / Q000737:chemistry; D004305:Dose-Response Relationship, Drug; D005814:Genes, Viral; D066298:In Vitro Techniques; D051379:Mice; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013329:Structure-Activity Relationship; D018243:Teratocarcinoma / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000821:virology; D013723:Teratogens / Q000737:chemistry / Q000633:toxicity*; D014157:Transcription Factors / Q000378:metabolism*; D014162:Transfection; D014407:Tumor Cells, Cultured; D014635:Valproic Acid / Q000737:chemistry / Q000633:toxicity*
D000927:Anticonvulsants; D017931:DNA Primers; D018160:Receptors, Cytoplasmic and Nuclear; D013723:Teratogens; D014157:Transcription Factors; D014635:Valproic Acid